Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance to Provide Genotyping for Sankyo in Potential Theranostics Deal

NEW YORK, Oct. 3 (GenomeWeb News) - Genaissance has licensed its HAP genotyping technology to Sankyo of Japan, the companies said today.


Under the agreement, the two firms aim to discover and validate genetic markers related to drug response and create a diagnostic test to guide therapy. Genaissance will receive license fees as well as payments for genotyping clinical samples. In addition, the company will have certain rights to co-develop and co-commercialize a companion genetic test.


Last month, Genaissance signed a deal with another Japanese pharma firm, Otsuka Pharmaceutical. "We hope to see more such agreements with Japanese companies in the future," said Genaissance CEO Kevin Rakin in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.